Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients
Inserm · Université Paris-Saclay · +37 more institutions
Abstract
T cell activation without exhaustion. Various strains of Christensenella minuta selectively boost the anti-cancer efficacy of ILDR and PD-L1 blockade, allowing emigration of intestinal PD-L1-expressing dendritic cells to tumor-draining lymph nodes. An interventional phase 2 study provides the proof-of-concept that ILDR can circumvent resistance to first- or second-line immunotherapy in cancer patients. Prospective clinical trials are warranted to define optimal dosimetry and indications for ILDR to maximize its therapeutic potential.
Citation impact
- FWCI
- 34.55
- Percentile
- 100%
- References
- 92
Authors
61- JCJianzhou ChenCorresponding
Inserm, Université Paris-Saclay, Institut Gustave Roussy, Shantou University, Cancer Hospital of Shantou University Medical College, La Ligue Contre le Cancer
- ALAntonin Lévy
Inserm, Université Paris-Saclay, Institut Gustave Roussy
- ATAi-Ling Tian
Inserm, Université Paris-Saclay, Institut Gustave Roussy, La Ligue Contre le Cancer
- XHXuehan Huang
Shantou University, Cancer Hospital of Shantou University Medical College
- GCGuoxin Cai
Inserm, Université Paris-Saclay, Institut Gustave Roussy, La Ligue Contre le Cancer
Topics & keywords
- Blockade
- Medicine
- Cancer
- Cancer research
- Pharmacology
- Oncology
- Internal medicine
- Receptor
- Good health and well-being
Funding
- AAmgen
- AAstraZeneca
- SSanofi
- FHF. Hoffmann-La Roche
- SUShantou University
- IRInnovative Research Group Project of the National Natural Science Foundation of China
- SFSeerave Foundation
- EEquipex
- BBeiGene
- ECEuropean CommissionAwards: 101095604, 825410, 101052444, ERC-2021-ADG
- DFDeutsche ForschungsgemeinschaftAwards: SFB 1371, 395357507
- ANAgence Nationale de la RechercheAwards: 18-IDEX-0001, ANR-21-RHUS-0005, ANR-21-RHUS-0017, ANR-18
- INInstitut National de la Santé et de la Recherche MédicaleAward: ANR-18-IDEX-0001
- NNNational Natural Science Foundation of China
- NSNatural Science Foundation of Guangdong Province
- UDUniversità degli Studi di Trento
- FAFondation ARC pour la Recherche sur le Cancer
- LCLigue Contre le CancerAward: 17563
- UDUniversité de Bourgogne
- APAstellas Pharma
- DKDeutsche KrebshilfeAward: 70113964
- INInstitut National Du Cancer
- ESEuropean Society for Medical Oncology
- FNFriedrich Naumann Stiftung
- UZUniversität zu Köln
- IGInstitut Gustave-Roussy
- DGDirection Générale de l’offre de Soins
- SUShantou University Medical College
- PPharmaMar
- OPOno Pharmaceutical
- UDUniversité de ParisAwards: 18-IDEX-0001, ANR-18-IDEX-0001
- INInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
- NINational Institutes of HealthAwards: ZIA BC 011343, -0001, CA271915, R01 grant
- GGenentech
- ESEMD Serono
- LILabex Immuno-OncologyAward: ANR-18-IDEX-0001
- NCNational Cancer InstituteAwards: ZIA BC 011343, CA274291
- MMSDAVENIR
- CCHIST-ERA